John Schindler, PhD

Assistant Professor
Cancer Immunobiology Center, Microbiology

Contact Information

UT Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390

Office Phone: 214-648-1229
Office Fax: 214-648-1252

john.schindler@utsouthwestern.edu

Biography

NAME: John Schindler, Ph.D. POSITION TITLE: Assistant Professor, Cancer Immunobiology Center INSTITUTION AND LOCATION DEGREE (if applicable) YEAR(s) FIELD OF STUDY Brown University, Providence, RI B.S. 1968 Chemistry Massachusetts Institute of Technology Ph.D. 1978 Biochemistry B. Selected peer-reviewed publications (in chronological order). Do not include publications submitted or in preparation. PUBLICATIONS (1995 ¿ 2002; 14 total): Sausville, E.A., Headlee, D., Stetler-Stevenson, M., Jaffe, E.S., Solomon, D., Figg, W.D., Herdt, J., Kopp, W.C., Rager, H., Steinberg, S.M., Ghetie, V., Schindler, J., Uhr, J., Wittes, R.E. and Vitetta, E.S. Continuous infusion of the Anti-CD22 immunotoxin, IgG-RFB4-SMPT-dgA in patients with B cell lymphoma: a Phase I study. Blood, 85:3457-3465, 1995. Stone, M., Sausville, E., Headlee, D., Lucas, E., Figg, W., Stetler-Stevenson, M-A., Jaffe, E., Solomon, D., Lush, R., Senderowitz, A., Ghetie, V., Schindler, J., Uhr, J., and Vitetta, E.S. A Phase I study of bolus vs. continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA in patients with B cell lymphoma. Blood, 88(4):1188-1197, 1996. Engert, A., Schnell, R., Schindler, J., Radszuhn, A., Hatwig, M-T., Drillich, S., Schon, G., Bohlen, H., Tesch, H., Hansmann, M-L., Barth, S., Ghetie, V., Uhr, J., Diehl, V. and Vitetta, E. A phase I-study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood, 89(2):403-410, 1997. Schnell, R., Vitetta, E., Schindler, J., Ghetie, V., Hell, K., Borchmann, P., Barth, S., Drillich, S., Diehl, V. and Engert, A. A phase II multicenter trial of bolus infusion of the anti-CD25 ricin A-chain immunotoxin RFT5-dgA in patients with refractory Hodgkin¿s lymphoma. Leukemia & Lymphoma, 30:5-6:525-537, 1998. Schnell, R., Vitetta, E., Schindler, J., Borchmann, P., Barth, S., Ghetie, V., Hell, K., Drillich, S., Diehl, V. and Engert, A. Treatment of refractory Hodgkin¿s lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia, 14:1:129-135, 2000. Messmann, R.A., Vitetta, E.S., Headlee, D., Senderowicz, A.M., Figg, W.D., Schindler, J., Michiel, D.F., Creekmore, S., Steinberg, S.M., Kohler, D., Jaffe, E.S., Stetler-Stevenson, M., Chen, H., Ghetie, V. and Sausville, E.A. A phase I study of combination therapy with immunotoxins IgG-HD37-dgA and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B-cell lymphoma. Clinical Cancer Research, 6(4):1302-13, 2000. Schindler J., Sausville, E., Messmann, R., Uhr, J.W., and Vitetta, E.S. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with Non-Hodgkin¿s lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials. Clinical Cancer Research, 7:255-258, 2001. Andre-Schmutz, I., Le Deist, F., Hacein-Bey, S., Vitetta, E., Schindler, J., Chedeville, G., Vilmer, E., Fischer, A. and Cavazzana-Calvo, M. . Improving immune reconstitution without GVHD following hematopoietic stem cell transplantation by infusion of donor T lymphocytes ex vivo depleted of alloreactive cells by a CD25-specific immunotoxin Lancet, 360:130-137, 2002.

Education

Graduate SchoolMassachusetts Institute of Technology (1978)

Research Interests

Antibody therapy
Clinical Trials
GVHD

Publications

Clinical evaulation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma

R. Schnell, P. Borchmann, J.O. Stakk, J. Schindler, V. Ghetie, E.S. Vitetta and A. Engert , Leukemia , 2003; (In press)

Improving immune reconstitution without GVHD following hematopoietic stem cell transplantation by infusion of donor T lymphocytes ex vivo depleted of alloreactive cells by a CD25-specific immunotoxin

I. Andre-Schmutz, F. Le Deist, S. Hacein-Bey, E. Vitetta, J. Schindler, G. Chedeville, E. Vilmer, A. Fischer and M. Cavazzana-Calvo , Lancet , 2002; (360):130-137

Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: A strategy for GVHD prophylaxis in allogenic peripheral blood stem cell transplantation

S.R. Solomon, T. Tran, C.S. Carter, S. Donnelly, N. Hensel, J. Schindler, E. Bahceci, V. Ghetie, J. Michalek, D. Mavroudis, E.J. Read, E.S. Vitetta and A.J. Barrett , Cytotherapy , 2002; (4):395-406

The toxicity of deglycosylated ricin A-chain containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: A retrospective analysis of patients in five clinical trials

J. Schindler, E. Sausville, R. Messmann, J.W. Uhr and E.S. Vitetta , Clinical Cancer Research , 2001; (7):255-258